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Summary
Quantitative sensory testing (QST) is used in a variety of pain disorders to
characterize pain and predict prognosis and response to specific therapies.
In this study, we aimed to confirm results in the literature documenting
altered QST thresholds in sickle cell disease (SCD) and assess the test–retest
reliability of results over time. Fifty-seven SCD and 60 control subjects aged
8–20 years underwent heat and cold detection and pain threshold testing
using a Medoc TSAII. Participants were tested at baseline and 3 months;
SCD subjects were additionally tested at 6 months. An important facet of
our study was the development and use of a novel QST modelling
approach, allowing us to model all data together across modalities. We
have not demonstrated significant differences in thermal thresholds
between subjects with SCD and controls. Thermal thresholds were consis-
tent over a 3- to 6-month period. Subjects on whom hydroxycarbamide
(HC) was initiated shortly before or after baseline testing (new HC users)
exhibited progressive decreases in thermal sensitivity from baseline to
6 months, suggesting that thermal testing may be sensitive to effective ther-
apy to prevent vasoocclusive pain. These findings inform the use of QST as
an endpoint in the evaluation of preventative pain therapies.
Keywords: sickle cell disease, quantitative sensory testing, vasoocclusive
pain, thermal thresholds, pressure pain threshold.
Quantitative sensory testing (QST) evaluates sensory function
using a set of standardized psychophysical procedures to
measure somatosensory responses to physiological stimuli
including temperature and pressure. QST provides an exten-
sion of the standard neurological examination by using care-
fully calibrated stimuli to examine the function of specific
peripheral and central nervous system pathways to assess
both gain and loss of function. The clinical utility of QST
has been well documented in a variety of pain disorders,
such as arthritis and neuropathic pain syndromes, and it has
been used to characterize pain and predict prognosis and
response to therapy, as described in several excellent reviews
(Arendt-Nielsen & Yarnitzky, 2009; Backonja et al, 2013;
Cruz-Almeida & Fillingim, 2014; Bouhassira & Attal, 2016;
Edwards et al, 2016a; Smith et al, 2017). While the majority
of this work has been done in adults (Coronado et al, 2014;
Edwards et al, 2016b; Moss et al, 2016, 2018; Maher et al,
2017), there is a growing body of literature in paediatric
disorders (Blankenburg et al, 2012, 2018; Kristensen et al,
2012; Cornelissen et al, 2014; Lieber et al, 2018; Teles et al,
2018). QST may also be used to elucidate underlying mecha-
nisms in order to evaluate whether targeted treatments may
be effective (Grosen et al, 2013) and to measure somatosen-
sory profiles and changes in physiological responses over
time (Geber et al, 2011).
In sickle cell disease (SCD), the nature of vasoocclusive
crisis (VOC), factors underlying the transition from acute to
chronic pain and the wide variability in the pain experi-
ence between individuals are poorly understood. Optimal
management for this complex pain syndrome remains highly
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problematic despite over four decades of basic and clinical
research in the field (Ballas et al, 2012). Hydroxycarbamide
(HC) and, more recently, L-glutamine are the only medications
which have been approved by the US Food and Drug Adminis-
tration for use in the prevention of VOC (Ware, 2015; Ware
et al, 2017; Quinn, 2018).
Investigations of new therapies to treat and prevent SCD
pain are hampered by the lack of objective outcome mea-
sures available to assess efficacy and rely heavily on highly
subjective measures, such as patient pain reports and number
of days spent in hospital. Analysing SCD pain on a more
mechanistic basis through QST may provide a means to
develop more patient-specific therapies to treat pain as well
as to prevent the transition to chronic or neuropathic pain.
In this study we aimed to further evaluate the seemingly
ambiguous results in the literature documenting altered QST
thresholds in SCD and assess the test–retest reliability of
results over time in a paediatric population.
Methods
Subject recruitment
Subjects with SCD and control subjects were recruited from
the Pediatric SCD Clinic at Nemours/Alfred I duPont Hospi-
tal for Children (NAIDHC). Additional controls were
recruited from a Nemours General Pediatric Clinic as well as
through advertisements within NAIDHC. Subjects with SCD
at their baseline state of health and healthy African American
controls aged 8–20 years were included in the study. In addi-
tion to the fact that children and young adults were most
accessible to the study institution, this population was
chosen in an effort to confirm and extend the results of a
recent study of QST in SCD (Brandow et al, 2013). Patients
with SCD genotypes SS, Sb0 thalassaemia and SC were eligi-
ble for the trial. Family groups as well as siblings and other
family members of individuals with SCD were included in
the control group, and individuals with sickle cell trait (SCT)
were not excluded. At enrolment, all subjects were required
to be at their baseline state of health and not in the midst of
any acute complication of SCD or other acute illness (i.e.
steady state). Subjects with SCD were excluded if they had
had an acute painful event severe enough to require inpatient
treatment with opioids within 2 weeks of enrolment. SCD
and control subjects were excluded if they had significant
neurocognitive impairment which would prohibit under-
standing test procedures or had another chronic illness that
produced clinical pain. Subjects were compensated $70 after
each of the testing sessions.
Testing procedures
All subjects were tested at baseline (day 1) and 3 months
later. Subjects with SCD were also tested at 6 months from
baseline. Subjects were instructed not to take any pain
medication within 24 h prior to a testing session. If they
reported taking pain medication within 24 h, the testing
session was delayed. Thus, while subjects with chronic pain
were not excluded, those on a regular schedule of daily pain
medications were not able to participate if they could not
tolerate 24 h without medication. For testing, participants
were seated in a comfortable chair, positioned so they could
not see monitors, in a quiet room with controlled air
temperature (68–72°C). Testing was performed without a
parent, guardian or observer in the room as presence of a
parent during testing has been shown to influence results
(Zohsel et al, 2006). However, in the presence of the subject,
parent/guardian was permitted to undergo a test trial of the
planned thermal and pressure testing and was permitted to
observe testing procedures via video monitoring from an
adjacent room. Subjects were given 10 min to acclimatize to
the room temperature prior to beginning study procedures.
Each participant completed all testing procedures. All testing
was performed by a single research nurse.
Thermal testing
Thermal testing was performed using the TSAII Neurosen-
sory Analyzer (Medoc Ltd., Yishai, Israel) with a 9 cm2
thermode. Testing was performed in triplicate, on the volar
surface of the forearm. For triplicate testing, the thermode
was moved up the forearm with each test applied to a differ-
ent patch of skin to avoid retesting the same area. Thresholds
were assessed in the following order: (i) cold detection
threshold (cdt), (ii) heat detection threshold (hdt), (iii) cold
pain threshold (cpt) and (iv) heat pain threshold (hpt). The
baseline temperature of the probe was 32°C. Probe tempera-
tures were not permitted to exceed 48°C nor go below 0°C.
For thermal detection thresholds, the thermode temperature
was decreased/increased from baseline at a rate of 1°C/s and
for thermal pain threshold at a rate of 1.5°C/s. Testing was
performed using the Method of Limits, where participants
were instructed to press a button when the sensation in
question was first perceived. This method has been used in
other paediatric QST studies in SCD (Brandow et al, 2013;
O’Leary et al, 2014) as well as in adults (Campbell et al,
2016a) and requires the shortest testing duration of all meth-
ods, which is particularly desirable for a paediatric study. For
temperature detection thresholds (cdt and hdt) participants
were asked to indicate the point at which they first felt a
sensation of cold or heat, respectively. For pain thresholds
(cpt and hpt) participants were asked to indicate the point at
which these sensations first produced a painful sensation.
Please note that subjects detecting cold (cdt) or reporting
pain (cpt) with cold at higher temperatures than controls or
at baseline are exhibiting greater sensitivity. Conversely, for
heat detection thresholds (hdt) and heat pain thresholds
(hpt), more sensitivity means that subjects detected heat or
reported pain with heat at lower temperatures than control
subjects or at baseline.
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Pressure pain testing
An electronic algometer (SBMedic Electronics, Solna, Sweden)
with a 1 cm2 hard rubber probe was used to assess responses
to mechanical pressure (Brennum, 1989). Pressure was
increased steadily at a constant rate (50 kPA/s) and subjects
indicated when the sensation changed from pressure to the
slightest pain, at which point the application was immediately
terminated. Pressure pain thresholds were assessed in tripli-
cate at each of two body sites bilaterally: the trapezius mus-
cle and the proximal third of the brachioradialis (forearm).
Testing was done on non-overlapping skin sites. Pressure
was applied to the muscle belly only. Because of some con-
cern that pressure pain testing (PPT) might cause more anx-
iety and thus be less well tolerated than thermal testing for
this patient population, PPT was included as an optional
procedure to be done only at the last study visit for subjects
with SCD and controls.
Pain perception and anxiety
Anticipatory anxiety and perceived pain intensity were
assessed using a 10-point scale, with one indicating the low-
est level and 10 indicating the highest level. Before each ther-
mal or pressure testing session, subjects were instructed on
use of the scale. Prior to each testing session, participants
were asked to identify, using the scale, how “nervous, afraid
or worried” they were about the upcoming task to indicate
level of anxiety. Specifically, they were asked “Before we start
this testing I have a question. I would like you to tell me
how nervous or worried you are about doing this testing on
a scale of 1–10? One is not being worried at all and 10 being
the most worried you could be.” Subjects were queried at the
end of the testing session about how intense the experience
was for them (Lazaridou et al, 2018). Specifically, they were
asked “Now that we have finished testing I have another
question. On a scale of 1–10, how painful was this test? One
being not painful at all and 10 being the most pain you
could be in.”
Pain diary
Participants with SCD were asked to keep a daily pain diary
starting at the time of initial testing and continued until all
follow-up testing was completed. An Apple iPad miniTM
providing electronic access to the diary was distributed to
each subject at the time of enrolment and paper diaries with
the same questions as those on the iPad were provided as
back up. The electronic Pain Diary was written in the PHP
and JavaScript programming languages and was accessible via
a username and password protected website. All data, includ-
ing usernames and passwords, was stored in REDCap via its
API (Harris et al, 2009). Subjects were asked to document
each episode of pain, identify parts of their body affected by
pain on the Collaborative Health Outcomes Information
Registry (CHOIR) body map (http://choir.stanford.edu),
indicate duration of pain symptoms, maximum severity of
pain and type of medication administered, and answer some
questions regarding the impact of pain on daily functioning.
The diary was available between 6:30 pm and 3 am each day.
Entries from previous days were not permitted.
Clinical data
Information regarding SCD genotype, current treatment regi-
men (e.g. chronic blood transfusions, HC), number of health
care provider contacts for VOC (clinic visits, hospitalizations
and Emergency Room visits) over the past 3 years and his-
tory of previous SCD complications was gathered from the
electronic medical record (EMR) at NAIDHC. Baseline hae-
moglobin, white blood cell (WBC) and reticulocyte counts
were also collected. Control subjects or their parent/guardian
were asked to disclose whether or not they carried SCT, or if
they were unsure of their SCT status.
Biomarkers
For SCD subjects only, prior to initial and at 6-month fol-
low-up testing, blood was drawn into citrate anticoagulant
tubes for measurement in plasma of lactate dehydrogenase
(LDH) activity (a marker of haemolysis), and high-sensitivity
C-reactive protein [hs-CRP; a marker of inflammation shown
to correlate with hospitalization for vasoocclusive pain in
SCD (Krishnan et al, 2010)]. LDH and hs-CRP levels were
evaluated using standard methods (Krishnan et al, 2010).
Statistical methods
Baseline characteristics. Baseline clinical and demographic
data were summarized by group (SCD versus control) using
means and standard deviations or frequencies and percent-
ages, as appropriate.
SCD versus controls. To assess differences between SCD and
controls on QST values, a longitudinal general linear model
was used to model the technical replicate measurements
repeated at baseline and 3 months. The raw QST values
themselves were shifted for the purposes of modelling to
delta temperature values that reflect the absolute temperature
deviation from the instrument’s reference temperature of
32°C, so that each QST value could be modelled together.
Model terms included group, time point, modality, age, sex,
pre-test anxiety, the three-way and each two-way interaction
between group, time point and modality. A compound sym-
metric correlation structure was used to account for the
strong correlation among the repeated measures within sub-
jects and modality at each time point (Fitzmaurice et al,
2011). Robust standard errors were computed using the
Huber sandwich estimator (Liang & Zeger,1986). A similar
longitudinal general linear model was fitted to only the SCD
Quantitative Sensory Testing in Sickle Cell Disease
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patients, and included baseline, 3- and 6-month follow-up
data and adjustment for additional covariates, including HC
(none, beginning within 5 months before baseline, beginning
at least 5 months before baseline), transfusions (none, begin-
ning within 5 months before baseline, beginning at least
5 months before baseline) and genotype. Linear contrasts
were used to estimate modality-specific group means and dif-
ferences between groups or between time points (Casella &
Berger, 2002).
Thermal composite score. From these QST models, we esti-
mated a novel thermal composite score (TCS). The TCS can
be estimated simply by averaging all the absolute temperature
deviations across all modalities (cdt, cpt, hdt and hpt). It is
an aggregated measure of a subject’s thermal sensitivity
across modalities in terms of the absolute temperature devia-
tions of their QST measurements from the instrument’s ref-
erence temperature of 32°C.
Test–retest reliability. To assess test–retest reliability of QST
scores, we fitted longitudinal general linear models adjusted
for covariates, as mentioned above, to each QST modality
and TCS separately and used the intraclass correlation coeffi-
cients (ICCs) from those models as a measure of the within-
subject agreement of QST scores for each modality and TCS
across technical replicates over time.
Power calculation. In a frequently cited paper, Brandow et al
(2013) reported significantly increased thermal sensitivity in
children with SCD compared with African American con-
trols. We powered our study using data from Brandow et al
(2013), anticipating between-group effect sizes of 0.46 for
heat threshold (difference of approximately 2.5 degrees) and
0.58 (difference of approximately 6.3 degrees) for cold
threshold. With 60 subjects per group, we expected to have
80% power to detect an effect size of 0.52 or greater using a
two-sided t-test with a 5% type I error rate.
Biomarker correlations. Correlations of baseline biomarker
levels with baseline QSTs in terms of the averages of techni-
cal replicates within participant and modality were computed
for the SCD subjects using Spearman’s rho.
Analysis of new HC users. As a retrospective nested pre-post
study, we analysed a subset of “new” HC users consisting of
SCD subjects in whom HC was initiated within 1 month
prior to or at any time between their baseline and last QST
test session (Table I). To do this, we constructed a longitudi-
nal general linear model and linear contrasts as described
above, but without covariate adjustment due to the small
subset sample size.
SAS version 9.4 (SAS Institute, Cary, NC, USA) was used
for all statistical analyses. The significance level for all tests
was set a priori at 0.05.
Results
Study population and baseline characteristics
Sixty SCD subjects and 60 control subjects were enrolled in
the study. Three subjects with SCD did not complete the
study. One patient was lost to follow-up after undergoing
baseline testing. One subject was removed from study after
baseline testing and another after the second testing session
when they were started on long-acting opioids to treat
chronic pain and thus were not able to tolerate 24 h without
pain medications to permit testing per protocol. Fifty-seven
SCD and 60 controls completed all thermal testing. SCD and
controls were similar in age and gender. Table II provides
information on age, gender and sickle cell diagnosis and
summarizes information on pertinent medical history, base-
line laboratory data and ongoing treatment (chronic transfu-
sion therapy or HC). There were no subjects on medications
to treat neuropathic pain.
Overall, thermal and pressure testing was well tolerated
with no reported adverse events, and after baseline testing no
patient refused subsequent testing. No subject reported the
occurrence of vasoocclusive symptoms related to testing
procedures.
Thermal sensitivity
There were no significant differences in thermal thresholds
between SCD and control subjects at baseline or month 3
(Table III, Table SI). There was no correlation between
Table I. For the subset of subjects with sickle cell disease who started HC just prior to or shortly after baseline testing, this table describes the
timing of HC initiation in relation to QST testing sessions and shows the rise in MCV from baseline test date to 6-month testing.
Subject Timing of HC initiation in relation to QST testing Change in MCV from QST1 to QST 3
1 HC initiated 29 days before QST session 1 87 to 88
2 HC initiated 21 days before QST session 1 91 to 100
3 HC initiated on day of QST session 2 95 to 105
4 HC initiated 18 days after QST session 1 77 to 87
5 HC initiated 50 days after QST session 1 100 to 114
6 HC initiated 128 days after QST session 1 77 to 90
HC, hydroxycarbamide; MCV, mean corpuscular volume; QST, quantitative sensory testing.
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thermal thresholds and pre-test anxiety or post-test pain per-
ception scores (data not shown). Age did not significantly
associate with thermal thresholds except among SCD subjects
whose cdt increased, on average, by 0.14°C per year
(P = 0.01). In subjects with SCD, there was no significant
association between thermal thresholds and genotype, gender,
chronic transfusion therapy, history of stroke or acute chest
syndrome, number of VOCs in the 3 years prior to
Table II. Baseline demographic and haematological data of study participants.
Participants with SCD (n = 60) Control participants (n = 60)
Age, years (mean  SD) 13.6  3.8 12.7  3.2
Female, N (%) 33 (55.0) 35 (58.3)
Sickle cell trait status, N (%)
Reported positive 17 (28.3)
Reported negative 24 (40.0)
Unsure 19 (31.7)
Sickle cell diagnosis, N (%)
SS 42 (70.0)
SC 17 (28.3)
Sb0 thalassaemia 1 (1.7)
History of stroke, N (%) 8 (13.3)
History of ≥2 episodes of acute chest, N (%) 30 (50.0)
Number of VOC (inpatient or outpatient), N (%)
0 21 (35.0)
1–5 25 (41.7)
6–10 5 (8.3)
>10 9 (15.0)
Hydroxycarbamide use, N (%) 14 (23.3)
Chronic blood transfusions, N (%) 16 (26.7)
Baseline hematological data, mean  SD
Haemoglobin (g/l) 98.1  14.6
WBC count (109/l) 10.99  4.63
Reticulocyte count (%) 7.50  4.34
hs-CRP* (mg/l) 3.78  4.99
LDH (iu/l) 426.42  166.59
hs-CRP, high sensitivity C-reactive protein; LDH, lactate dehydrogenase; SCD, sickle cell disease; SD, standard deviation; VOC, venocclusive cri-
sis; WBC, white blood cell.
*n = 58.
Table III. Difference in thermal thresholds and TCS expressed in degrees Celsius, between SCD and controls at baseline and 3-month testing,
adjusted for age, sex and pre-test anxiety (TCS was also adjusted for modality).
Modality Time point
Control SCD Difference (SCD  Control)
Mean SE Mean SE Mean SE 95% CI P
cdt Day 1 28.28 0.31 28.98 0.22 0.70 0.38 0.05, 1.44 0.07
cdt Month 3 27.96 0.40 27.97 0.38 0.01 0.55 1.08, 1.09 0.99
cpt Day 1 22.44 0.86 22.73 0.89 0.29 1.24 2.14, 2.72 0.82
cpt Month 3 22.68 0.91 22.70 0.76 0.03 1.19 2.31, 2.36 0.98
hdt Day 1 35.69 0.32 35.31 0.27 0.38 0.42 1.19, 0.44 0.37
hdt Month 3 35.67 0.27 36.05 0.33 0.38 0.43 0.46, 1.22 0.38
hpt Day 1 40.00 0.43 39.94 0.41 0.06 0.59 1.23, 1.10 0.92
hpt Month 3 40.19 0.44 40.32 0.47 0.13 0.64 1.13, 1.39 0.84
TCS Day 1 6.24 0.27 5.88 0.26 0.36 0.37 1.09, 0.38 0.34
TCS Month 3 6.31 0.28 6.42 0.26 0.12 0.38 0.64, 0.87 0.76
cdt, cold detection threshold; CI, confidence interval; cpt, cold pain threshold; hdt, heat detection threshold; hpt, heat pain threshold; SCD, sickle
cell disease; SE, standard error; TCS, thermal composite score.
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enrolment, baseline haemoglobin, WBC and reticulocyte
counts, LDH or hs-CRP (data not shown). There was a posi-
tive correlation between hs-CRP and LDH (P < 0.001).
While there was some variability in mean thermal thresh-
olds among SCD subjects over time, there were no signifi-
cant differences between any two time points (Table IV,
Table SII). In addition, there were no significant differences
in mean thermal testing results between baseline and
3 months for controls subjects (data not shown) and no
significant statistical interactions between modality and study
group or time point variables in our models (all P ≥ 0.30,
Tables SI and SII), which suggests the TCS is a reasonable
outcome for comprehensively assessing these comparisons.
QST measurements were internally consistent in SCD and
control subjects for cpt, hdt and hpt (each ICC > 0.55), but
not necessarily for cdt (ICC = 0.37) or TCS (ICC = 0.38).
We analysed the internal consistency of QST measurement in
SCD subjects alone over all three time points and the ICC
results were similar.
The group of six subjects with SCD in whom HC was
initiated within 1 month prior or between baseline and
final testing (described in Table I) demonstrated trends
toward reductions in both thermal sensitivity and significant
reductions in both thermal pain threshold measurements, as
well as the TCS, over time following HC initiation
(Table V).
Pressure pain thresholds
Sickle cell disease and control subjects opting in for pressure
testing had similar demographics (Table SIII). The SCD
subjects showed significantly higher sensitivity to pressure
pain than controls (reported pain at lower levels of pressure)
in the brachioradialis, but not the trapezius (Table VI,
Table SIV).
Pain diary
Compliance with daily entries into pain diary was poor, with
only 43.3% of patients entering data ≥50% of the days and
66.6% entering data ≥25% of the days. In these limited data,
there was no significant correlation between the number of
pain days and thermal thresholds in those who filled out
their diaries ≥25% or 50% of the time.
Discussion
Our study using QST did not demonstrate any differences in
thermal sensitivity or pain thresholds between subjects with
SCD and healthy African American controls. Our results are
similar to a recent report by Bakshi et al (2017). Interest-
ingly, in our patients who elected to undergo PPT, we have
also demonstrated significantly increased sensitivity to pres-
sure pain in the brachioradialis but not the trapezius, as
Table IV. Thermal test–retest over 6 months for subjects with SCD only, adjusted for age, sex, hydroxycarbamide,* transfusions,* genotype (SS,
S Beta 0, or SC), and pre-test anxiety (TCS was also adjusted for modality).
Modality
Day 1 Month 3 Month 6
Difference (Month
3  Baseline)
Difference (Month
6  Baseline)
Difference (Month
6  Month 3)
Mean SE Mean SE Mean SE Diff 95% CI P Diff 95% CI P Diff 95% CI P
cdt 28.60 0.68 27.78 0.75 27.91 0.71 0.81 1.66, 0.04 0.06 0.68 1.46, 0.10 0.09 0.13 1.08, 0.82 0.79
cpt 22.35 1.01 22.52 0.95 21.78 1.19 0.17 2.10, 2.44 0.89 0.57 3.07, 1.92 0.65 0.74 1.59, 3.07 0.53
hdt 35.69 0.70 36.23 0.74 36.17 0.72 0.54 0.30, 1.38 0.21 0.48 0.40, 1.35 0.28 0.06 0.84, 0.96 0.89
hpt 40.32 0.75 40.50 0.79 41.29 0.78 0.19 1.03, 1.41 0.76 0.97 0.26, 2.20 0.12 0.78 2.04, 0.47 0.22
TCS 6.26 0.66 6.61 0.68 6.94 0.73 0.34 0.38, 1.06 0.35 0.68 0.10, 1.46 0.09 0.33 -0.40, 1.07 0.37
cdt, cold detection threshold; CI, confidence interval; cpt, cold pain threshold; Diff, difference; hdt, heat detection threshold; hpt, heat pain
threshold SCD, sickle cell disease; SE, standard error; TCS, thermal composite score.
*Three level variable: no use (reference level), use started within 5 months, use starting more than 5 months ago.
Table V. Thermal test–retest data over 6 months for “new HC” user SCD subgroup (n = 6).
Modality
Day 1 Month 3 Month 6
Difference (Month 3  Day 1) Difference (Month 6  Day 1)
Mean Mean Mean Mean 95% CI P Mean 95% CI P
cdt 29.32 29.00 27.57 0.32 2.09, 1.41 0.70 1.75 4.62, 1.12 0.22
cpt 23.90 22.38 18.01 1.52 4.32, 1.28 0.28 5.89 11.15, 0.64 0.03
hdt 35.02 35.37 37.39 0.34 0.95, 1.64 0.59 2.37 0.55, 5.29 0.11
hpt 39.34 41.92 43.09 2.58 0.19, 5.34 0.07 3.75 0.94, 6.56 0.01
TCS 5.29 6.48 8.73 1.19 0.07, 2.32 0.04 3.44 1.63, 5.25 <0.01
cdt, cold detection threshold; CI, confidence interval; cpt, cold pain threshold; HC, hydroxycarbamide; hdt, heat detection threshold; hpt, heat
pain threshold SCD, sickle cell disease; TCS, thermal composite score.
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previously demonstrated by Campbell et al (2016a). QST was
well tolerated by children as young as 8 years of age and was
relatively quick, taking only 10–15 min to complete the full
set of thermal testing used in this study.
Quantitative sensory testing is a potentially valuable tool
that could be useful in assessing the effectiveness of preventa-
tive pain therapies in SCD. Outcome measures used in
current SCD clinical trials are fairly limited and highly prob-
lematic. Pain reports are subjective and, unless daily pain
diary entries are used, subject to recall bias. Reduction in
pain medication use is similarly difficult to track. As demon-
strated by our study, compliance with pain diaries can
be poor. Most pharmaceutical intervention trials last
6–12 months. Changes in rate of hospitalization or outpa-
tient visits for VOC are often used, but incidence of severe
VOC can vary tremendously from year to year in a given
patient, and many patients do not seek medical attention fre-
quently for their crises, making it difficult to document a
true change over the typical span of a clinical trial using
these measures. Decreased thermal and/or pressure sensitivity
and pain thresholds documented in response to a given treat-
ment modality could serve as less subjective markers of
response to a preventative pain therapy for use in a short
duration clinical trial than these standard outcome measures.
For changes in QST thresholds following an intervention
to be useful in clinical trials, there must be relative stability
in a given patient’s baseline results. To our knowledge, our
study is the first to document consistency of QST results in
SCD subjects over time. Our ICC results showed that
between-subject variability accounted for between 1/3 and
2/3 of the total variance, depending on the QST modality,
suggesting that thermal thresholds tend to be consistent over
a 3- to 6-month period in subjects with SCD as well as in
African American controls. Age was investigated as a possible
source of inconsistency among the repeated QST measure-
ments, however, we noted no associations between subject
age and QST means or QST replicate standard deviations
(data not shown) either in descriptive analyses or in statisti-
cal models. Our longitudinal modelling results between the
second and third testing session in subjects with SCD were
highly consistent, indicating that reliability may improve
once subjects have experience with the testing procedures.
Based on these data, we would recommend that for clinical
trial use, subjects undergo a “practice” QST session to famil-
iarize themselves with the procedures and alleviate any anxi-
ety prior to their baseline QST testing.
Of particular interest is our finding that in six subjects
with SCD on whom HC therapy was initiated within
1 month prior to, or between their baseline and final QST
test session, all exhibited progressively decreased sensitivity in
thermal threshold parameters. While the small sample size
and the variable start times of HC relative to QST test
sessions limit the conclusions that can be drawn, these
results, suggesting that thermal testing may be sensitive to an
effective treatment to prevent vasoocclusive pain, should be
followed up in larger, more rigorous studies.
Several groups have recently reported on QST in SCD
(Brandow et al, 2013, 2019; O’Leary et al, 2014; Jacob et al,
2015; Brandow & Panepinto, 2016; Campbell et al, 2016a;
Ezenwa et al, 2016; Bakshi et al, 2017; Veluswamy et al,
2018), raising interest in the use of QST as a modality to
help elucidate the mechanisms of pain in SCD. Interestingly,
Veluswamy et al (2018) demonstrated stronger and more
rapid vasoconstriction in SCD subjects in response to ther-
mal stimuli, most significantly cold, compared to controls,
suggesting that heightened vascular autonomic reactivity may
be linked to cold-related VOC in SCD. Overall, however, the
results of these studies have been variable, with some groups
showing altered thermal thresholds in patients with SCD as
compared to control subjects, while other have shown no
differences. While Campbell et al (2016a) did demonstrate
reduced heat pain tolerance in the adult subjects with SCD
when compared to African American controls, they were
unable to demonstrate any differences in hpts. The volar sur-
face of the forearm was used as the site of testing in our
work, as well as in the studies reported by Bakshi et al
(2017) and Campbell et al (2016a).
In contrast, Brandow et al (2013) reported significantly
increased cdt and cpts and decreased hdt and hpts (indicat-
ing increased sensitivity to heat and cold) in children with
SCD compared with an African American control group
when testing was performed at the thenar eminence. No
differences were observed when the foot was the tested area
(Brandow et al, 2013). In a more recent study, the same
Table VI. Model-adjusted* differences in pressure pain thresholds between participants with SCD and control participants by site of test.
Location
Control SCD Difference (SCD  Control)
Mean SE Mean SE Mean 95% CI P
Brachioradialis – Left 450.42 19.45 372.50 21.63 77.92 136.09, 19.76 0.009
Brachioradialis – Right 408.78 19.45 322.83 21.74 85.94 144.26, 27.62 0.004
Trapezius – Left 427.26 19.54 388.33 21.63 38.92 97.20, 19.35 0.190
Trapezius – Right 425.72 19.45 402.65 21.63 23.07 81.23, 35.09 0.435
CI, confidence interval; SCD, sickle cell disease; SE, standard error.
*Adjusted for age, sex and pre-test anxiety (data reported in kPA/s).
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group showed that subjects with SCD had increased sensitiv-
ity to cold pain in the hand, but not in the foot, during
hospitalization for acute painful events when compared to
baseline health (Brandow et al, 2019). A study by O’Leary
et al (2014) showed no significant differences between
children with SCD and African American controls in thermal
detection or pain thresholds when testing was performed on
the forearm. However, when testing was performed on the
thenar eminence, they found that children with SCD were
less sensitive to cold and heat detection, and had increased
sensitivity to cold pain when compared to controls (O’Leary
et al, 2014). Thus, we suggest that differences between our
results and those of Brandow et al (2013) may be explained,
at least in part, by different body sites used for testing. While
our study was similar in size and overall design to the study
reported by Brandow et al (2013), these authors performed
testing on the thenar eminence while in our study, testing
was performed on the volar surface of the forearm. Testing
on the forearm allows for movement of the probe to a new,
non-overlapping skin site between each test. It is possible
that repeated testing on the same skin site, as would be
necessary when using a small area such as the thenar emi-
nence, could produce sensitization at that site. Additionally,
testing on glabrous (thenar) versus hairy skin (forearm)
could have contributed to the differences observed between
our studies, as thermal detection and pain thresholds have
been shown to vary based on nociceptive innervation
(Granovsky et al, 2005).
In a follow-up report, Brandow and Panepinto (2016)
proposed cpt and hpt cut-off values indicative of impairment
in children with SCD. When we apply these cut-offs to our
African American cohort, we find that 50 (83%) of the con-
trols and 49 (82%) of the SCD group would be considered
to have impaired cpt and 51 (85%) of the controls and the
SCD group would be considered to have impaired hpt.
When Bakshi et al, (2017) applied the thresholds for impair-
ment suggested by Brandow and Panepinto (2016) for chil-
dren with SCD, they found that 68% of the SCD and 56% of
the control participants had “impaired” cpt values, while
90% of the SCD and 85% of the control participants fell in
the abnormal range for hpt. While published studies have
established normal standards based on age and sex, African
Americans have been shown to have reduced tolerance to
experimentally-induced pain (Edwards & Fillingim, 1999;
Campbell et al, 2005). Normative QST values for a healthy
African American paediatric population are not yet well
established. Furthermore, ethnicity within the SCD popula-
tion varies considerably so African American norms may not
be directly applicable to all SCD patients. In view of our
findings and those of Bakshi et al (2017), use of the previ-
ously suggested normative QST values warrants caution.
An important facet of our study was the development and
use of our novel thermal testing composite score, the TCS.
Constructing the delta temperature values necessary for com-
puting the TCS allowed us to model all data together across
modalities (cdt, cpt, hdt and hpt). Compared to separately
modelling QST modality data, the more parsimonious model
of the deltas requires the estimation of far fewer model
parameters, making more efficient use of data, and can be
used to directly evaluate how interventions interact with
modality, as we have done. Modelling the delta temperature
values representing the elements of the TCS allows thermal
testing response to an intervention to be expressed compre-
hensively and, if QST responses do not appear to interact
with and depend on modality, crude TCS can be estimated
in the clinic simply by averaging all of a patient’s delta tem-
perature values across modalities. We believe this approach
to handling QST replicates is more powerful and more versa-
tile than other methods of handling QST replicates, such as
averaging the technical replicates, which tends to underesti-
mate and underutilize the variability in QST assessments.
A significant strength of our study was that all testing was
performed by a single, highly trained individual. While we
believe that this contributed to the consistency of our results,
we recognize that this may not be possible in many clinical
or research settings. As such, training and standardization of
procedures seem critical. Different methods of QST evaluate
different physiological parameters.
Specific testing may measure peripheral sensitivity using
thermal or mechanical stimulation; other testing, such as
temporal summation, measures central sensitization (hyper-
sensitivity of the CNS), while the combination of two tasks
applied heterotopically measure endogenous opioid tone.
Central sensitization is a prime suspect for pain facilitation
and the transition from acute to chronic pain in patients
with SCD. In a recent adult SCD cohort, those who experi-
enced greater central sensitization reported more clinical
pain, VOCs, catastrophizing, negative mood and poorer sleep
continuity (Campbell et al, 2016b). Our study was limited in
that we did not utilize some of the more complex QST tech-
niques, such as temporal summation or conditioned pain
modulation, where Campbell et al (2016a) saw differences
between SCD and control subjects. We chose to forgo these
modalities out of concern that they might not be feasible in
a paediatric age group. Rather, static measures of pressure
and thermal sensitivity testing were employed which, in
adult populations, have shown good-to-excellent reliability
(Marcuzzi et al, 2017; Nothnagel et al, 2017). However,
Bakshi et al (2017) was able to complete heat pain tolerance
and temporal summation testing successfully in paediatric
subjects, supporting the development of these testing modali-
ties for clinical trial use. In addition, our subjects were
relatively young and many of them were on HC or chronic
transfusion therapy. Thus, as a group, they exhibited a low
pain phenotype, which may have resulted in less pronounced
threshold differences between SCD and healthy controls.
Unfortunately, the current study is unable to assess whether
QST is altered secondary to transition from acute to chronic
pain, given the short time frame and lack of pain in these
young patients. Future studies may benefit from evaluating
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temporal summation response and its evolution over time in
children as they move through adolescence and into adult-
hood. Alterations in these responses could potentially be an
early warning marker for central sensitization or pain facilita-
tion, while habituation in response could suggest resiliency.
Another limitation of our study was the limited informa-
tion on baseline pain levels in test subjects. No univariable
association was found between the thermal thresholds and
number of health care encounters for VOC in the 3 years
prior to study entry. Pain managed at home was not quanti-
fied due to concern about recall, and there were no measures
of impact of pain on quality of life. However, the require-
ment that subjects be off all pain medications for at least
24 h at the time of testing eliminated patients with chronic
pain significant enough to require chronic, scheduled pain
medications as well as those with severe acute pain. Poor
compliance with the daily pain diary impeded our ability to
establish a detailed correlation between the degree of pain
experienced and QST results. For an upcoming clinical trial
in which our group plans to use a pain diary, we will
compensate subjects $1 per day to improve compliance.
Our data shows that, in the absence of the introduction of
a new sickle cell-directed, ongoing pharmacological or trans-
fusion therapy, QST results remained relatively consistent
over a 6-month period. In contrast, a subset of individuals
on whom HC was initiated close to the time of baseline test-
ing, exhibited progressively decreasing thermal sensitivity.
Based on our study results, we caution against the use of a
predefined “abnormal” range for QST thresholds. Instead, it
may be more meaningful to evaluate changes in an individ-
ual patient’s QST thresholds over time as these changes may
indicate a progression of disease (i.e. from an acute to
chronic or neuropathic pain phenotype) or response to a
new therapy. Our study provides preliminary data to support
the future examination of QST as a potentially valuable out-
come measure for use in early phase clinical trials to indicate
response to a preventative pain therapy.
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